Mikrobiel (Moxifloxacin)

Moxifloxacin, the active ingredient in Mikrobiel, is a fluoroquinolone antibiotic presented as an intravenous solution for intravenous use. It treats severe bacterial infections that require hospital‑based IV therapy, including pneumonia, sinusitis, skin‑structure and intra‑abdominal infections. It is indicated for patients who cannot take oral therapy and for infections caused by susceptible Gram‑negative and Gram‑positive organisms.

GNH USA supplies Mikrobiel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to EU quality standards and provides reliable logistics for clinical use.

Moxifloxacin is employed to treat bacterial infections affecting several organ systems.

- Community‑acquired bacterial pneumonia: effective eradication of susceptible pathogens causing lung infection. - Acute bacterial sinusitis: rapid resolution of sinus inflammation due to susceptible bacteria. - Complicated skin and skin‑structure infections: control of severe dermal infections resistant to oral therapy. - Complicated intra‑abdominal infections: treatment of mixed‑organism infections requiring IV antibiotics. - Severe bacterial infections requiring IV therapy: broad‑spectrum coverage for hospitalized patients with serious infections.

Adverse reactions may occur with intravenous moxifloxacin therapy.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools, usually self‑limiting. - Headache: transient cranial discomfort. - Injection site pain: local discomfort at the infusion site.

Serious or Rare Side Effects: - Tendon rupture: especially Achilles tendon, may occur without warning. - QT interval prolongation: risk of ventricular arrhythmias. - Severe allergic reactions: anaphylaxis, skin rash, or angioedema. - Clostridioides difficile infection: colitis due to disruption of gut flora.

Use of intravenous moxifloxacin requires careful clinical assessment. - Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic impairment: use with caution in patients with liver disease. - History of tendon disorders: avoid use due to increased risk of tendon rupture. - Concomitant QT‑prolonging drugs: monitor ECG for arrhythmia risk. - Pregnancy and lactation: assess risk versus benefit before prescribing. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Moxifloxacin may interact with several medications; clinical monitoring is advised.

Major Interactions (Avoid): - Concurrent fluoroquinolones: increased risk of toxicity. - Systemic corticosteroids: heightened tendon rupture risk. - Other QT‑prolonging agents: additive risk of cardiac arrhythmias. - Warfarin: potential enhancement of anticoagulant effect.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs: possible renal adverse effects. - Cyclosporine: increased nephrotoxicity risk. - Theophylline: may raise serum theophylline concentrations. - Rifampin: may reduce moxifloxacin plasma levels.